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Abstract. Trypanosoma cruzi DNA was amplified from an intracranial biopsy and peripheral blood of an HIV
patient with encephalitis; this episode was indicative of AIDS and congenital Chagas disease. The analysis of a micro-
satellite locus revealed a multiclonal parasite population at the brain lesion with a more complex minicircle signature
than that profiled in blood using restriction fragment length polymorphism (RFLP)-PCR and low stringency single
primer (LSSP) PCR. Interestingly, different sublineages of T. cruzi II were detected in blood and brain by means of
spliced-leader and 24s ribosomal-DNA amplifications. Quantitative-competitive PCR monitored the decrease of para-
sitic load during treatment and secondary prophylaxis with benznidazole. The synergy between parasiticidal plus anti-
retroviral treatments probably allowed the patient a longer survival than usually achieved in similar episodes. This is the
first case report demonstrating a differential distribution of natural parasite populations and sublineages in Chagas
disease reactivation, showing the proliferation of cerebral variants not detectable in peripheral blood.
INTRODUCTION
Due to the increasing control of transmission routes medi-
ated by vector, blood transfusion, and organ transplant, con-
genital transmission of Trypanosoma cruzi has emerged in
terms of public health.1 Congenital cases are frequently
asymptomatic, passing unnoticed unless specific tests are
made.1,2 The acquired immunodeficiency syndrome (AIDS)
pandemic, with 1.4 million infected people in endemic regions
for Chagas disease, may lead to reactivation of quiescent
chronic T. cruzi infections.3,4
Natural T. cruzi populations are composed of multiclonal
strains with different biological properties such as replication
rates, drug susceptibility, virulence, and tissue tropism, which
may be implicated in the clinical forms of the disease.5,6 These
strains cluster within two major phylogenetic lineages, T.
cruzi I and T. cruzi II, with 5 lesser subdivisions within T.
cruzi II, whose phylogenetic relationships are still under de-
bate.7,8 The high sensitivity of PCR-based typing strategies
provides direct assessment of parasite genetic diversity in
clinical specimens without the need of culture isolation,9–11
which may underestimate natural population complexity due
to strain selection during culture expansion. Herein, we re-
port the differential diagnosis of chagasic encephalitis in a
patient with presumptive cerebral toxoplasmosis due to
AIDS, applying PCR in a surgical sample of brain tissue and
peripheral blood specimens, not detectable using current
parasitological methods. Furthermore, PCR-based identifica-
tion of T. cruzi lineages and profiling of microsatellite and
minicircle signatures were assessed directly from the clinical
specimens, providing evidence of a differential host tissue
distribution of natural parasitic populations.
CASE REPORT
A 29-year-old HIV-positive Argentinian man, born in Bue-
nos Aires, was hospitalized in February 2003 with left hemi-
paresis and a history of protracted headaches of 1 month of
evolution. Magnetic resonance imaging showed multiple
masses on the left brain hemisphere (Figure 1A) and anti-
toxoplasma IgG serodiagnosis was positive, although near the
cutoff line (6 IU/mL). Consequently, treatment of presump-
tive cerebral toxoplasmosis was implemented. As the patient
did not respond to the specific treatment, an intracranial bi-
opsy guided by CT-scan was indicated to determine the eti-
ology of the encephalitis. Histologic analysis exhibited edema
and high lymphocyte counts but did not reveal any protozoan
forms. Thus, we applied PCR procedures targeted to T. gon-
dii B112 and T. cruzi minicircle (kDNA)13 and satellite (sat-
DNA) sequences14 from DNA extracts of the brain tissue
specimen, which only revealed T. cruzi DNA, indicative of
cerebral Chagas disease. Microhematocrit analysis2 did not
show any bloodstream forms, but the high sensitivity of
kDNA-PCR (0.4 log parasite genome equivalents/mL)13 al-
lowed detection of T. cruzi DNA in peripheral blood. Be-
sides, anti–T. cruzi serodiagnosis also resulted positive
(ELISA titer R: 2.7, cutoff < 1, and indirect hemaglutination
titer 1/256, cutoff < 1:32). Thus, on the basis of T. cruzi DNA
amplification and seroreactivity, the patient received a final
diagnosis of chagasic encephalitis. Accordingly, trypanocidal
therapy with benznidazole (5 mg kg−1 day−1) was adminis-
tered. Treatment (tmt) response was monitored by competi-
tive-quantitative PCR (Q-PCR) on peripheral blood,13 which
initially revealed approximately 280 parasites genome equiva-
lents/mL of blood (2.4 log. pge/mL) (Figure 1B; April 2003).
Treatment regimen was modified 25 days later because the
patient presented polymorphic erythema. At that time, the
parasitic load had decreased to 1.4 logpge/mL (Figure 1B;
May 2003). After the remission of symptoms, tmt was re-
started for 60 days leading to further decrease of parasitemia
to undetectable loads (Q-PCR below 1.09 log. and kDNA-
PCR below 0.4 log. pge/mL; Figure 1B, August 2003). There-
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after, secondary prophylaxis with benznidazole was initiated
(5 mg kg−1 day−1 twice a week) with persistently negative
PCR findings (Figure 1B; August 2003 to February 2005)
accompanied by a good clinical evolution without neurologic
symptoms. Magnetic resonance imaging showed a reduction
of perilesional edema although brain mass did not remit (not
shown); two cerebral spinal fluid samples withdrawn during
post-treatment follow-up were negative when examined by
microscopy and kDNA-PCR (not shown). The anti-T. cruzi
immunologic response persisted positive throughout follow-
up. Antiretroviral tmt (ART) promoted a decrease of HIV
viral load from > 500,000 copies/mL to undetectable levels (<
1.7 logHIV copies/mL), accompanied with an increase of
CD4+ cell counts from 22/mm3 to 194/mm3 (Figure 1B). After
30 months of survival, the patient continues under anti–T.
cruzi prophylaxis, ART, and anticonvulsive tmt. This study
was approved by the hospital review board and ethical com-
mittees of the institutions; written informed consent was re-
quired in agreement with the guidelines of the International
Conference on Harmonization.
Molecular profiling of parasitic populations and lineages
involved in Chagas disease reactivation. To characterize the
genetic diversity of the patient´s parasitic populations found in
peripheral blood and brain tissue samples, the 330-bp kDNA
amplicons were profiled using low stringency single primer
(LSSP) and restriction fragment length polymorphism
(RFLP) PCR strategies10,11 (Figure 2). Interestingly, mini-
circle signatures from brain tissue parasites exhibited a dif-
ferent profile than that obtained from bloodstream parasites
at time of diagnosis (Figure 2A). The minicircle signatures
detected in brain tissue showed a higher number of amplicons
than those in blood, suggesting a higher diversity of parasite
variants. This diversity was further explored by amplification
of a microsatellite marker, known as TAC 15,9 which revealed
a multiclonal population in the brain chagoma (amplicons of
128, 131, and 134 bp; Figure 2B, br) whereas a homozygous
and conserved population was detected in bloodstream at
time of diagnosis and during treatment follow-up (amplicons
of 131 bp; Figure 2B, bl0 and bl45, respectively).
The bloodstream parasite minicircle signatures were char-
acterised during antiparasite treatment (Figures 2A and 2C).
The RFLP-PCR and LSSP-PCR profiles obtained from T.
cruzi kDNA in blood collected 45 days after initiation of tmt
revealed a reduction in the number and/or the relative pres-
ence of certain minicircle subclasses compared with the pat-
terns of the pretreatment population (Figures 2A and 2C,
lanes bl0 and bl45). These findings suggested a differential tmt
response of certain parasite variants until the complete clear-
ance of the parasitemia at the end of tmt.
To identify the parasite lineages in peripheral blood and
brain chagoma, the intergenic region of the spliced-leader
genes was amplified by a multiplex PCR assay,15 revealing T.
cruzi II in both clinical specimens (Figure 2D, lanes 1 and 4).
Furthermore, heminested amplification of the D7 domain of
the 24s ribosomal RNA genes15 allowed to distinguish T.
cruzi II b/e (rDNA group 2/2) at the brain lesion and T. cruzi
IId (rDNA group 1/2) in bloodstream (Figure 2D, lanes 2 and
5, respectively).
DISCUSSION
According to Centers for Diseases Control and Prevention,
3 of the 12 case-defining opportunistic infections for AIDS
Group IV are parasitoses, namely toxoplasmosis, cryptospo-
ridiosis, and isosporidiosis. However, in endemic regions for
Chagas disease, T. cruzi should be included among the po-
tential opportunistic pathogens indicative of AIDS.3,4 In this
scenario, the PCR provided a rapid differential and sensitive
diagnosis of T. cruzi reactivation allowing prompt adminis-
tration of specific chemotherapy, which contributed to the
patient´s long survival. This case further illustrated the useful-
ness of Q-PCR to follow-up parasitic response to treatment
and secondary prophylaxis. Moreover, prospective Q-PCR
could aid in assessing the risk of reactivation to implement
primary prophylaxis. It is worth noting that the synergy of
parasiticidal secondary prophylaxis plus antiretroviral treat-
ment may have allowed the patient a longer survival than
usually achieved in similar episodes.3,4
To date, few cases of chagasic reactivation due to AIDS
have been described in detail.3,4 The typical epidemiologic
sequence of events was to acquire T. cruzi infection in rural
areas of endemicity and to move to urban centers where HIV
FIGURE 1. A, Magnetic resonance imaging (T1 with gadolinium)
showing cerebral mass lesions at time of diagnosis of encephalitis
(February 2003). I, transversal section; II, sagital section. B, Diagno-
sis and follow-up of the AIDS patient with chagasic encephalitis. The
parasitic load was estimated by means of quantitative-competitive
PCR. Log. pge/mL: logarithm of parasite genomic equivalents/ml of
blood. : CD4 cells count. : HIV load.
FIGURE 2. Molecular typing of T. cruzi lineages and populations
implicated in cerebral Chagas reactivation. A, LSSP-PCR profiles of
330-bp kDNA amplicons. B, Electrofluorogram of T. cruzi “TAC 15”
microsatellite locus (values in the scale given in bp). C, AluI + HinfI
RFLP-PCR of 330-bp kDNA amplicons. LSSP-PCR and RFLP-PCR
were analyzed by 10% acrylamide gel electrophoresis and Sybr
Green dye staining. Br, brain tissue; bl0, blood sample collected be-
fore tmt with benznidazole; bl45, blood sample collected 45 days after
start of tmt. D, Ethidium bromide–stained 3% agarose gel showing
PCR-based typing of T. cruzi lineages. Lanes 1 and 4, spliced-leader-
based PCR; Lanes 2 and 5, 24s ribosomal DNA-based heminested
PCR using primers D75-D76 (first round) and D71-D76 (second
round)15; Lane 3, 100-bp molecular weight marker.
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infection was acquired, leading to opportunistic disease as
immunosuppression ensued.3,4 However, the case reported
herein most likely acquired Chagas disease through vertical
transmission. This was assumed because a) the patient was
born in a nonendemic area, b) did not have any contact with
triatomine vectors, did not receive transfusions, did not use
intravenous drugs, and c) his mother was seropositive for
Chagas disease. Congenital Chagas disease cannot be pre-
vented, but early diagnosis and treatment achieve very high
cure rates.2,13 This stresses out the public health importance
of surveying all newborns to seropositive mothers in nonen-
demic areas for Chagas disease.
The role of T. cruzi parasitemia and genetic make-up on
the onset of chagasic reactivation due to AIDS, as well as the
impact of HIV infection in T. cruzi genetic diversity, are
poorly explored fields of clinical parasitology.16,17 Compara-
tive zymodeme studies of parasite stocks obtained from HIV-
positive patients with T. cruzi coinfection did not reveal sig-
nificant differences regarding the tissue tropism or repartition
of the strains.16 Remarkably, this case is the first evidence of
a differential distribution of T. cruzi populations associated
with reactivation, showing the proliferation of cerebral para-
site multiclonal populations, belonging to a sublineage not
detectable in peripheral blood, indicative of lineage-
histotropism in Chagas disease.
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